CARSGEN-B (02171.HK): First Patient Dose of CT0596 in China Phase I
NewTimeSpace News: On 13 October 2026, CARsgen Therapeutics Holdings Limited (stock code: 02171) announced that CT0596, an allogeneic CAR T-cell product targeting BCMA, has completed the first patient dose in its registrational Phase I clinical trial in China. CT0596 is intended for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
The announcement stated that CT0596 is developed using CARsgen's proprietary THANK-u Plus® platform and is currently being evaluated in the registrational Phase I trial for R/R MM, and that the IIT results of CT0596 have been presented as a poster presentation at the 2026 Annual Congress of the European Hematology Association (EHA). Previous IITs showed that CT0596 demonstrated preliminary favorable tolerability and encouraging efficacy signals in R/R MM and primary plasma cell leukemia.
CARsgen said it plans further investigation in additional plasma cell malignancies and autoimmune diseases mediated by autoreactive plasma cells. The Company is a biopharmaceutical company focusing on developing innovative CAR T-cell therapies, with end-to-end capabilities covering target discovery, preclinical research, clinical development and commercial-scale production.
- CARSGEN-B(02171.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 66.66 million, loss narrowed by 11.52% YoY
- CARSGEN-B (02171.HK): Universal CAR-T product CT1190B receives NMPA IND approval for treatment of relapsed/refractory large B-cell lymphoma
- CARsgen Therapeutics (02171.HK) CT041 Postoperative Adjuvant Therapy Study Results Accepted for ESMO 2026 Poster Presentation
- CARSGEN-B(02171.HK): Kailimei® Secures NMPA Marketing Approval, the World’s First CAR-T Cell Therapy for Solid Tumors
- CARSGEN-B (02171.HK) plans to issue up to 23.7 million shares by placement, with estimated net proceeds of HKD 461.96 million
